Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models
Abstract
Normalizing the tumor microenvironment with losartan prevents tumor-induced hearing loss and enhances radiation response in schwannoma rodent models.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 14, 2021
- Source ID
- 10.1126/scitranslmed.abd4816
Entities
People
- Alona Muzikansky
- Alyssa Brown
- Anat Stemmer-Rachamimov
- Grace Y. Lee
- Jessica E Sagers
- Jie Chen
- Jun Ren
- Konstantina M. Stankovic
- Lei Xu
- Limeng Wu
- Lukas D Landegger
- Luo Zhang
- Meenal Datta
- Na Zhang
- Rakesh Jain
- Samuel Early
- Saša Vasilijić
- Scott R. Plotkin
- Wenjianlong Zhou
- William W Ho
- Xing Gao
- Yanling Zhang
- Yao Sun
- Zhenzhen Yin
Organizations
- American Association for Cancer Research
- Cancer Research Institute
- Capital Medical University
- Children's Tumor Foundation
- Gates Foundation
- Harvard Medical School
- Lauer Tinnitus Research Center, Massachusetts Eye and Ear
- Lustgarten Foundation for Pancreatic Cancer Research
- Massachusetts General Hospital
- Nancy Sayles Day Foundation
- National Cancer Institute
- National Foundation for Cancer Research
- National Institute on Deafness and Other Communication Disorders
- St. Mark's School
- UC San Diego Medical Center, Hillcrest
- United States Department of Defense